A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20117 in Participants With Advanced Solid Tumors
Latest Information Update: 14 Jul 2023
At a glance
- Drugs PM 1080 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 14 Jul 2023 New trial record